Gemmer Asset Management’s 9 Meters Biopharma NMTR Stock Holding History

Gemmer Asset Management’s Portfolio NMTR Stock Details NMTR Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2021 Q1	–	Sell	-75	Closed	-$1K	–	1530
2020 Q4	$1K	Buy	+75	New	+$1.25K	﹤0.01%	1412

Other funds holding NMTR

OrbiMed New York $5.05B AUM 125.28% 1-Year Est. Return

Adage Capital Partners Boston, Massachusetts $64.8B AUM 42.7% 1-Year Est. Return

Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return

TLP

Tri Locum Partners New York $713M AUM 68.92% 1-Year Est. Return

BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return

CVI Holdings Wilmington, Delaware $116M AUM 5.68% 1-Year Est. Return

Millennium Management New York $240B AUM 35.51% 1-Year Est. Return

MWNA

Marshall Wace North America New York $23.5B AUM 46.46% 1-Year Est. Return

Geode Capital Management Boston, Massachusetts $1.61T AUM 30.72% 1-Year Est. Return

Two Sigma Advisers New York $51.4B AUM 31.07% 1-Year Est. Return

Gemmer Asset Management's NMTR Position: Q1 2021 in Review

Gemmer Asset Management sold out of 9 Meters Biopharma (NMTR) in Q1 2021, closing a stake of 75 shares — an estimated $1K sold.

Gemmer Asset Management first reported a position in NMTR in Q4 2020 and held it in 1 quarter. The position peaked at $1K in Q4 2020. 90 funds tracked by Wall St. Rank hold NMTR as of Q1 2021.

Gemmer Asset Management reported no remaining 9 Meters Biopharma position as of Q1 2021 after selling out during the quarter.
Gemmer Asset Management sold 75 9 Meters Biopharma shares in Q1 2021, an estimated $1K.
Gemmer Asset Management first reported a position in 9 Meters Biopharma in Q4 2020 and held it in 1 quarter.
Gemmer Asset Management's 9 Meters Biopharma position peaked at $1K in Q4 2020.
90 funds tracked by Wall St. Rank held 9 Meters Biopharma as of Q1 2021.

Based on Gemmer Asset Management's 13F filing for Q1 2021, filed 20 Apr 2021.